Neogen Expects Regulatory Review of Genomics Sale to Zoetis to Conclude in Early 2027

By Public Technologies
  • Zoetis has offered to divest certain Australian assets to help secure clearance for its acquisition of Neogen's global Genomics business.
  • Regulatory review is expected to conclude in early 2027. Australian and New Zealand competition authorities continue reviewing the transaction.
  • The definitive sale agreement was announced March 2, 2026. Completion remains subject to customary closing conditions and regulatory approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neogen Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-447166), on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk